Allison M McFall1, David W Dowdy, Carla E Zelaya, Kerry Murphy, Tracey E Wilson, Mary A Young, Monica Gandhi, Mardge H Cohen, Elizabeth T Golub, Keri N Althoff. 1. *Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; †Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY; ‡Department of Community Health Sciences, State University of New York Downstate Medical Center, Brooklyn, NY; §Department of Medicine, Georgetown University Medical Center, Washington, DC; ‖Department of Medicine, University of California San Francisco, San Francisco, CA; ¶Department of Medicine and the CORE Center, Cook County Health and Hospitals System, Chicago, IL; and #Rush University, Chicago, IL.
Abstract
BACKGROUND: Stark racial/ethnic disparities in health outcomes exist among those living with HIV in the United States. One of 3 primary goals of the National HIV/AIDS Strategy is to reduce HIV-related disparities and health inequities. METHODS: Using data from HIV-infected women participating in the Women's Interagency HIV Study from April 2006 to March 2011, we measured virologic failure (HIV RNA >200 copies/mL) after suppression (HIV RNA < 80 copies/mL) on highly active antiretroviral therapy. We identified predictors of virologic failure using discrete time survival analysis and calculated racial/ethnic-specific population-attributable fractions (PAFs). RESULTS: Of 887 eligible women, 408 (46%) experienced virologic failure during the study period. Hispanic and white women had significantly lower hazards of virologic failure than African American women [Hispanic hazard ratio, (HR) = 0.8, 95% confidence interval: (0.6 to 0.9); white HR = 0.7 (0.5 to 0.9)]. The PAF of virologic failure associated with low income was higher in Hispanic [adjusted hazard ratios (aHR) = 2.2 (0.7 to 6.5), PAF = 49%] and African American women [aHR = 1.8 (1.1 to 3.2), PAF = 38%] than among white women [aHR = 1.4 (0.6 to 3.4), PAF = 16%]. Lack of health insurance compared with public health insurance was associated with virologic failure only among Hispanic [aHR = 2.0 (0.9 to 4.6), PAF = 22%] and white women [aHR = 1.9 (0.7 to 5.1), PAF = 13%]. By contrast, depressive symptoms were associated with virologic failure only among African-American women [aHR = 1.6 (1.2 to 2.2), PAF = 17%]. CONCLUSIONS: In this population of treated HIV-infected women, virologic failure was common, and correlates of virologic failure varied by race/ethnicity. Strategies to reduce disparities in HIV treatment outcomes by race/ethnicity should address racial/ethnic-specific barriers including depression and low income to sustain virologic suppression.
BACKGROUND: Stark racial/ethnic disparities in health outcomes exist among those living with HIV in the United States. One of 3 primary goals of the National HIV/AIDS Strategy is to reduce HIV-related disparities and health inequities. METHODS: Using data from HIV-infectedwomen participating in the Women's Interagency HIV Study from April 2006 to March 2011, we measured virologic failure (HIV RNA >200 copies/mL) after suppression (HIV RNA < 80 copies/mL) on highly active antiretroviral therapy. We identified predictors of virologic failure using discrete time survival analysis and calculated racial/ethnic-specific population-attributable fractions (PAFs). RESULTS: Of 887 eligible women, 408 (46%) experienced virologic failure during the study period. Hispanic and white women had significantly lower hazards of virologic failure than African American women [Hispanic hazard ratio, (HR) = 0.8, 95% confidence interval: (0.6 to 0.9); white HR = 0.7 (0.5 to 0.9)]. The PAF of virologic failure associated with low income was higher in Hispanic [adjusted hazard ratios (aHR) = 2.2 (0.7 to 6.5), PAF = 49%] and African American women [aHR = 1.8 (1.1 to 3.2), PAF = 38%] than among white women [aHR = 1.4 (0.6 to 3.4), PAF = 16%]. Lack of health insurance compared with public health insurance was associated with virologic failure only among Hispanic [aHR = 2.0 (0.9 to 4.6), PAF = 22%] and white women [aHR = 1.9 (0.7 to 5.1), PAF = 13%]. By contrast, depressive symptoms were associated with virologic failure only among African-American women [aHR = 1.6 (1.2 to 2.2), PAF = 17%]. CONCLUSIONS: In this population of treated HIV-infectedwomen, virologic failure was common, and correlates of virologic failure varied by race/ethnicity. Strategies to reduce disparities in HIV treatment outcomes by race/ethnicity should address racial/ethnic-specific barriers including depression and low income to sustain virologic suppression.
Authors: R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn Journal: Lancet Date: 2001-04-14 Impact factor: 79.321
Authors: Jane M Simoni; David Huh; Ira B Wilson; Jie Shen; Kathy Goggin; Nancy R Reynolds; Robert H Remien; Marc I Rosen; David R Bangsberg; Honghu Liu Journal: J Acquir Immune Defic Syndr Date: 2012-08-15 Impact factor: 3.731
Authors: E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo Journal: Ann Intern Med Date: 2001-07-03 Impact factor: 25.391
Authors: S J Gange; Y Barrón; R M Greenblatt; K Anastos; H Minkoff; M Young; A Kovacs; M Cohen; W A Meyer; A Muñoz Journal: J Epidemiol Community Health Date: 2002-02 Impact factor: 3.710
Authors: T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: Thomas Yi; Jennifer Cocohoba; Mardge Cohen; Kathryn Anastos; Jack A DeHovitz; Naoko Kono; David B Hanna; Nancy A Hessol Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Judith A Cook; Mardge H Cohen; Jane Burke; Dennis Grey; Kathryn Anastos; Lynn Kirstein; Herminia Palacio; Jean Richardson; Tracey Wilson; Mary Young Journal: J Acquir Immune Defic Syndr Date: 2002-08-01 Impact factor: 3.731
Authors: Cynthia A Kleeberger; Jennifer Buechner; Frank Palella; Roger Detels; Sharon Riddler; Rebecca Godfrey; Lisa P Jacobson Journal: AIDS Date: 2004-03-05 Impact factor: 4.177
Authors: Ziad El-Khatib; Anna Mia Ekstrom; Ashraf Coovadia; Elaine J Abrams; Max Petzold; David Katzenstein; Lynn Morris; Louise Kuhn Journal: BMC Public Health Date: 2011-02-08 Impact factor: 3.295
Authors: Sara C Keller; Baligh R Yehia; Florence O Momplaisir; Michael G Eberhart; Amanda Share; Kathleen A Brady Journal: AIDS Patient Care STDS Date: 2014-03-21 Impact factor: 5.078
Authors: Tracey E Wilson; Emma Sophia Kay; Bulent Turan; Mallory O Johnson; Mirjam-Colette Kempf; Janet M Turan; Mardge H Cohen; Adaora A Adimora; Margaret Pereyra; Elizabeth T Golub; Lakshmi Goparaju; Lynn Murchison; Gina M Wingood; Lisa R Metsch Journal: Am J Prev Med Date: 2018-04-12 Impact factor: 5.043
Authors: Jonathan Ross; Uriel R Felsen; Chinazo O Cunningham; Viraj V Patel; David B Hanna Journal: AIDS Res Hum Retroviruses Date: 2017-05-22 Impact factor: 2.205